JAB-3068 is theF second SHP2 inhibitor approved by the FDA to enter clinical development. JAB-3312, the second generation SHP2 inhibitor designed by Jacobio has more potent anti-tumor activities. Both compounds have been granted orphan drug designation by the FDA for the treatment of esophageal cancer (including esophageal squamous cell carcinoma).
Therapy | Indications | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|
KRAS G12Ci Combination Therapy | KRAS G12C mut NSCLC |
|
Phase IIa initiated in Jul, 2022 |
|
Combo w/EGFRi | Osimertinib progressed NSCLC |
|
FPI in Jan, 2022 |
|
Combo w/PD-1 mAb | NSCLC, HNSCC, ESCC |
|
Phase IIa initiated with FPI in Feb, 2022 |
|
Mono | BRAF Class 3/NF1 LOF mutant solid tumers |
|
Therapy | Indications | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|
Mono | ESCC, HNSCC, NSCLC, ACC |
|
||
Combo w/PD-1 mAb | ESCC, HNSCC, NSCLC |
|
JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.
Therapy | Indications | Phase I | Phase IIa | Pivotal | Recent progress |
---|---|---|---|---|---|
Mono | NSCLC |
|
Pivotal study FPI in Sep 2022 |
||
Mono | CRC, PDAC and other solid tumors |
|
Phase IIa FPI in Mar 2022 |
||
Mono Combo w/EGFR mAb |
NSCLC, CRC, PDAC |
|
FPI in May 2022 in Europe |
||
Mono | 1L NSCLC with STK11 co-mutation |
|
FPI in China in Sep 2022 |
||
Combo w/SHP2i | Advanced solid tumors |
|
FPI in May 2022 |
||
Combo w/EGFR mAb | CRC |
|
Phase IIa FPI in Jul 2022 |
||
Combo w/PD-1 mAb | NSCLC |
|
JAB-8263 class 1 innovative drug that is a Bromodomain and Extra-Terminal motif (BET) inhibitor independently developed by Jacobio. Preclinical studies have shown that JAB-8263 can effectively inhibit tumor growth at very low concentrations. In addition to solid tumors, hematological tumors are particularly sensitive to JAB-8263. Patients with hematological tumors and some types of solid tumors may benefit from the treatment of JAB-8263.
Therapy | Indications | IND | Phase I | Phase II | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
|||
Monotherapy | Solid Tumor |
|
First patient enrolled Feb, 2022 |
||
Monotherapy | MF, AML |
|
First patient enrolled Apr, 2021 |
JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.
Therapy | Indications | IND | Phase I | Phase II | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
IND Approved in China Oct, 2022 FPI in U.S Jan, 2023 |
JAB-BX102 is a humanized anti-CD73 monoclonal antibody (mAb)developed by Jacobio to inhibit the enzymatic activity of CD73. CD73 is the key node of adenosine pathway, and its inhibitors have broad therapeutic prospects for tumors dependent on adenosine pathway. Relevant studies have shown that adenosine promotes SHP2 phosphorylation, suggesting that anti-CD73 antibody can be combined with SHP2 inhibitor, which is also developed by Jacobio to benefit patients with advanced solid tumors.
Therapy | Indications | IND | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|---|
Mono and Combo w/ PD-1 antibody | Solid Tumor |
|
FPI in China Sep, 2022 |
Asset | Target | Modality | IND Schedule | Indications | Recent Development | Lead Optimization | IND-enabling | |
---|---|---|---|---|---|---|---|---|
IND-Enabling
|
JAB-26766 | PARP7 (I/O) |
Small molecule | 2023 IND | Solid tumors | Candidate nominated, entering into IND enabling studies in Jan 2022 |
|
|
JAB-24114 | Undisclosed (Tumor metabolic pathway) |
Small molecule | 2023 IND | Solid tumors, Hematological malignancies | Candidate nominated, entering into IND enabling studies in Mar 2021 |
|
||
JAB-BX300 | Undisclosed (RAS pathway) |
Monoclonal antibody | 2023 IND | Solid tumors | Candidate nominated, entering into IND enabling studies in Mar 2021 |
|
||
JAB-23400 | KRASmulti (RAS pathway) |
Small molecule | 2023 IND | PDAC, CRC, NSCLC | Candidate nominated, entering into IND enabling studies in Feb 2021 |
|
||
JAB-30300 | P53 Y220C (P53 pathway) |
Small molecule | 2023 IND | Solid tumors | Candidate nominated, entering into IND enabling studies in Jul 2022 |
|
||
Lead Optimization
|
JAB-BX400 | HER2-STING (I/O) |
iADC | 2024 IND | Solid tumors | Payload has been selected and patent filed in Dec 2021 |
|
|
JAB-X1800 | CD73-STING (I/O) |
iADC | 2024 IND | Solid tumors | Payload has been selected and patent filed in Dec 2021 |
|
||
JAB-22000 | KRAS G12D (RAS pathway) |
Small molecule | 2024 IND | PDAC, CRC, NSCLC | Lead series identified and patent filed in Nov 2020 |
|
Abbreviation: mAb = monoclonal antibody; ESCC = esophageal squamous cell carcinoma; HNSCC = head and neck squamous cell carcinoma; NSCLC = non CLC; KRAS amp = KRAS amplification; Lof = missing function; CRC = colorectal cancer; MF = bone marrow fibrosis; AML = acute myeloid leukemia; CRPC = castration resistant prostate cancer; HCC = hepatocellular carcinoma; PDAC = pancreatic ductal adenocarcinoma; Ind = new drug for clinical research or new drug application for clinical research.
As date of Sep 6, 2022